DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol

Abstract Background Fluoropyrimidine (FP) chemotherapies are commonly prescribed for upper and lower gastrointestinal, breast and head and neck malignancies. Over 16,000 people with cancer require FP chemotherapies per annum in Australia. Between 10 and 40% patients experience grade 3–4 (≥ G3) toxic...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Cassandra White, Hannah Wardill, Christine Paul, Timothy Price, Christos Karapetis, Mark Nalder, Matthew E. Burge, Ann Thomas, Chris Oldmeadow, Daniel Barker, Laura C. Edney, Janet Coller, Joanne Bowen, Cheri Ostroff, Bruce Cheek, Mel Carlson, Trumaine Rankmore, Adnan Nagrial, Stephen Clarke, Lorraine Chantrill, Stephen Ackland, Rodney J. Scott
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2024-11-01
سلاسل:	BMC Cancer
الموضوعات:	DPYD Fluoropyrimidine Pharmacogenomics Dihydropyrimidine dehydrogenase UGT1A1 Irinotecan
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12885-024-13122-8
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!